1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Coronary Vasospasm in 15 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Coronary Vasospasm: Spasm of the large- or medium-sized coronary arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm." | 9.10 | Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003) |
| "We sought to determine whether a potent Rho-kinase inhibitor fasudil prevents the occurrence of myocardial ischemia in patients with microvascular angina attributable to coronary microvascular spasm." | 5.10 | Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. ( Hirakawa, Y; Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A, 2003) |
| "We envisage the efficacy and safety of intra-arterial infusion of fasudil hydrochloride (IAF) for symptomatic vasospasm (SVS) after subarachnoid hemorrhage (SAH)." | 3.79 | Beneficial effect of selective intra-arterial infusion of fasudil hydrochloride as a treatment of symptomatic vasospasm following SAH. ( Chang, HS; Fujisawa, N; Hosono, A; Indo, M; Matsui, T; Nakamura, T; Okano, A; Oya, S; Suzuki, Y; Tsuchiya, T, 2013) |
| "We studied the antiischemic properties of fasudil, a Rho-kinase inhibitor, in conscious rabbits with coronary vasospasm induced by vasopressin and endothelin." | 3.71 | Antiischemic properties of fasudil in experimental models of vasospastic angina. ( Asano, T; Ikegaki, I; Sato, S; Shimokawa, H, 2001) |
| "Fasudil was effective in preventing ACh-induced coronary artery spasm and resultant myocardial ischemia in patients with vasospastic angina." | 2.70 | Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. ( Masumoto, A; Mohri, M; Shimokawa, H; Takeshita, A; Urakami, L; Usui, M, 2002) |
| "Fasudil is a ROCKs inhibitor which has potential benefits in coronary artery spasm and myocardial ischemia." | 2.45 | Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm. ( Dong, M; Yan, BP; Yu, CM, 2009) |
| "An 86-year-old woman was admitted with unstable angina pectoris." | 1.32 | [Inhibition of Rho-kinase by fasudil preventing anginal attacks associated with spastic angina: a case report]. ( Fukumoto, Y; Hiroki, J; Hirooka, Y; Shimokawa, H; Takeshita, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 11 (73.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suda, A | 1 |
| Takahashi, J | 1 |
| Hao, K | 1 |
| Kikuchi, Y | 1 |
| Shindo, T | 1 |
| Ikeda, S | 1 |
| Sato, K | 1 |
| Sugisawa, J | 1 |
| Matsumoto, Y | 2 |
| Miyata, S | 1 |
| Sakata, Y | 1 |
| Shimokawa, H | 10 |
| Taniguchi, Y | 1 |
| Funayama, H | 1 |
| Matsuda, J | 1 |
| Fujita, K | 1 |
| Nakagawa, T | 1 |
| Nakamura, T | 2 |
| Umemoto, T | 1 |
| Mitsuhashi, T | 1 |
| Ako, J | 1 |
| Momomura, S | 1 |
| Dong, M | 1 |
| Yan, BP | 1 |
| Yu, CM | 1 |
| Matsui, T | 1 |
| Hosono, A | 1 |
| Okano, A | 1 |
| Fujisawa, N | 1 |
| Tsuchiya, T | 1 |
| Indo, M | 1 |
| Suzuki, Y | 1 |
| Oya, S | 1 |
| Chang, HS | 1 |
| Mohri, M | 2 |
| Hirakawa, Y | 1 |
| Masumoto, A | 2 |
| Takeshita, A | 6 |
| Hoka, S | 1 |
| Kandabashi, T | 3 |
| Miyata, K | 2 |
| Kunihiro, I | 1 |
| Eto, Y | 2 |
| Morishige, K | 2 |
| Obara, K | 1 |
| Nakayama, K | 1 |
| Takahashi, S | 1 |
| Inokuchi, K | 1 |
| Ito, A | 1 |
| Fukumoto, Y | 2 |
| Matoba, T | 1 |
| Shiose, A | 1 |
| Nishida, T | 1 |
| Masuda, M | 1 |
| Morita, S | 1 |
| Hiroki, J | 1 |
| Hirooka, Y | 1 |
| Otsuka, T | 1 |
| Ibuki, C | 1 |
| Suzuki, T | 1 |
| Ishii, K | 1 |
| Yoshida, H | 1 |
| Kodani, E | 1 |
| Kusama, Y | 1 |
| Atarashi, H | 1 |
| Kishida, H | 1 |
| Takano, T | 1 |
| Mizuno, K | 1 |
| Seto, M | 1 |
| Katsumata, N | 1 |
| Amano, M | 1 |
| Kozai, T | 1 |
| Yamawaki, T | 1 |
| Kuwata, K | 1 |
| Egashira, K | 1 |
| Ikegaki, I | 3 |
| Asano, T | 3 |
| Kaibuchi, K | 2 |
| Sato, S | 1 |
| Lamping, KG | 1 |
| Urakami, L | 1 |
| Usui, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Early Intracoronary Administration of Fasudil Hydrochloride on Myocardial Perfusion in the Primary PCI of ST-elevation Myocardial Infarction: an Prospective, Randomized and Multicenter Trial[NCT03753269] | Phase 4 | 600 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Coronary Vasospasm
| Article | Year |
|---|---|
Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Coronary Artery Disease; Coronary Vasospasm; Humans; | 2009 |
[Basic and clinical studies on coronary vasospasm].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Calcium Channel Blockers; Coronary Artery Disease; Co | 2002 |
3 trials available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Coronary Vasospasm
| Article | Year |
|---|---|
Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Aged; Cardiovascular Agents; Coronary | 2003 |
Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Coronary Angiography; Coronary | 2008 |
Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Aged; Angina, Unstable; Coronary Angio | 2002 |
10 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Coronary Vasospasm
| Article | Year |
|---|---|
Coronary Functional Abnormalities in Patients With Angina and Nonobstructive Coronary Artery Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angina Pectoris; Coronary Angiography; Coronary | 2019 |
Super-selective intracoronary injection of Rho-kinase inhibitor relieves refractory coronary vasospasms: a case report.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged, 80 and over; Coronary Vasospasm; Humans; Inject | 2014 |
Beneficial effect of selective intra-arterial infusion of fasudil hydrochloride as a treatment of symptomatic vasospasm following SAH.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Coronary Angiography; Coronary Vasospasm | 2013 |
Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Calcium; Capillary Permea | 2003 |
Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Coronary Artery Bypass; Coronary Vasospasm; Dil | 2004 |
[Inhibition of Rho-kinase by fasudil preventing anginal attacks associated with spastic angina: a case report].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Aged, 80 and over; Angina, Unstable; Angioplast | 2004 |
Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Blotting, Western; Cor | 1999 |
Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Blotting, Western; Cor | 2001 |
Antiischemic properties of fasudil in experimental models of vasospastic angina.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angina Pectoris; Animals; Coronary Vasospasm; Disease | 2001 |
Enhanced contractile mechanisms in vasospasm: is endothelial dysfunction the whole story?
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Coronary Vasospasm; Endothelium, Va | 2002 |